Piperacillin versus clindamycin plus gentamicin for pelvic infections.
Piperacillin, a new semisynthetic penicillin, has broad spectrum activity against most clinically important aerobic and anaerobic bacteria. In the present study, piperacillin was compared with a combination of clindamycin and gentamicin for the treatment of 83 women with pelvic infection (42 with endometritis, 29 with posthysterectomy cuff infections, 11 with acute salpingitis, and one with a wound infection). There were 179 bacterial isolates, 98 (53%) aerobic and 81 (45%) anaerobic. Of the 42 patients treated with piperacillin, there were three (7.1%) clinical failures compared with one (2.4%) in the 41 patients treated with clindamycin-gentamicin. A single drug, piperacillin, was shown to be as safe and effective as the combined clindamycin plus gentamicin therapy for pelvic infections.
D000328:Adult; D002585:Cesarean Section; D002981:Clindamycin / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004716:Endometritis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008826:Microbial Sensitivity Tests; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy* / Q000382:microbiology; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy* / Q000382:microbiology; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000382:microbiology
D005839:Gentamicins; D002981:Clindamycin